Bedrijfsoverzicht
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company dedicated to the development and commercialization of medications designed for the treatment of dermatologic diseases within the United States market. Operating within the Healthcare sector and specifically the Biotechnology industry, the company focuses on creating drug-device combinations, such as its offering YCANTH (VP-102), which utilizes a GMP-controlled formulation to address specific skin conditions. The organization currently employs 76 individuals and holds a market capitalization of $87.78M, reflecting its status as a mid-cap entity in the specialized biotechnology space. With an annual revenue of $35.58M, the company's financial scale suggests it has moved beyond the early-stage development phase into a period where commercialization efforts are generating significant sales volume relative to its total market valuation.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $35.58M, yet it posted a net income of $-17,886,000 and an EBITDA of $-11,454,000, revealing a substantial gap between top-line growth and bottom-line profitability that points to a high-burn cost structure typical of commercializing biologic therapies. This financial reality is further underscored by a free cash flow of $-15,459,625, indicating that the company is currently consuming cash reserves to fund operations and expansion rather than generating surplus liquidity from its current business activities. The gross margin stands at 65.4%, which is healthy for the industry, but this is contrasted by an operating margin of -136.4% and a profit margin of -50.3%, highlighting that general and administrative expenses, along with cost of goods sold pressures, are significantly outpacing gross profits. On the balance sheet, the firm holds $30.15M in cash against $1.63M in debt, resulting in a debt-to-equity ratio of 6.59, which suggests a highly leveraged position relative to equity though the absolute debt load is small compared to cash holdings. Liquidity is supported by a current ratio of 2.59, indicating that the company possesses more than double the current assets required to cover its short-term liabilities. However, the return on equity is -240.4% and the return on assets is -14.7%, metrics that reveal that management effectiveness in generating shareholder value is currently negative due to the pre-profitability stage of the business model.
Waarderingsbeoordeling
The company presents a trailing P/E ratio of N/A and a forward P/E of -3.00, a discrepancy that implies earnings are currently negative and the forward metric reflects expectations of continued losses or a non-standard earnings trajectory rather than a traditional profit growth path. The price-to-book ratio is 3.55, indicating that the market is valuing the company at a significant premium of over three times its tangible book value, which often occurs in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.47 and an EV/EBITDA of -5.17 suggest that investors are pricing the stock based on revenue generation potential and future drug approvals rather than current earnings multiples. The 52-week high is $9.82 and the 52-week low is $3.28, meaning the stock has experienced a wide trading range and is currently positioned somewhere within this volatile band relative to its recent historical extremes. The beta value of 1.43 indicates that the stock price is expected to be 43% more volatile than the broader market, reflecting the high-risk nature of biotechnology investments where single clinical outcomes can drive significant price swings.
Growth & Income
Verrica Pharmaceuticals reported a revenue growth year-over-year of 1380.2%, while earnings growth is N/A due to the negative net income, illustrating that revenue expansion is occurring without a corresponding increase in profitability at this stage of development. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings and cash flow are being retained and reinvested into research, development, and commercialization efforts rather than distributed to shareholders. The absence of a dividend payout aligns with the company's lifecycle stage, where capital preservation and funding for the YCANTH platform are prioritized over income generation for investors. Overall, the growth profile is characterized by explosive top-line revenue expansion, whereas the income profile remains negative, creating a high-risk, high-reward dynamic typical of early-to-mid stage dermatology therapeutics companies focused on bringing novel treatments to market.